首页> 美国卫生研究院文献>British Journal of Clinical Pharmacology >Beta-adrenoceptor blockade and atrio-ventricular conduction in dogs. Role of intrinsic sympathomimetic activity.
【2h】

Beta-adrenoceptor blockade and atrio-ventricular conduction in dogs. Role of intrinsic sympathomimetic activity.

机译:β-肾上腺素受体阻滞和犬房室传导。内在拟交感神经活动的作用。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

1 Atrio-ventricular conduction and its modifications induced by six beta-adrenoceptor blocking agents and isoprenaline have been investigated in the anaesthetized dog using the extrastimulus technique and measuring atrial (AERP), nodal (NERP), global (GERP) effective refractory periods as well as global functional refractory period (GFRP). 2 When beta-adrenoceptor blockade was produced by (+/-)-propranolol (beta 1 + beta 2-adrenoceptor blockade) which is devoid of intrinsic sympathomimetic activity (ISA) but has membrane stabilizing effects (MSE), sotalol (beta 1 + beta 2-adrenoceptor blockade, no ISA, no MSE) and atenolol (beta 1-adrenoceptor blockade, no ISA, no MSE), all parameters were significantly increased. When beta-adrenoceptor blockade was achieved with pindolol (beta 1 + beta 2-adrenoceptor blockade) and practolol (beta 1-adrenoceptor blockade) which have ISA but no MSE, all parameters remained unchanged, as was also the case with (+)-propranolol, which has MSE but neither ISA nor beta-adrenolytic properties. 3 Isoprenaline at high doses significantly reduced the refractory periods but when infusion was stopped, marked but reversible conduction depression was observed. 4 It thus appears that beta-adrenoceptor blockade but not MSE is responsible for the onset of atrial and AV-conduction impairment and that ISA affords protection against this impairment.
机译:1已在麻醉犬中使用刺激技术并测量了心房(AERP),淋巴结(NERP),整体(GER​​P)有效不应期,研究了由6种β-肾上腺素受体阻滞剂和异丙肾上腺素诱导的房室传导及其修饰作为全球功能不应期(GFRP)。 2当(+/-)-普萘洛尔(β1 +β2-肾上腺素受体阻滞剂)产生β-肾上腺素受体阻滞剂时,它没有固有的拟交感神经活性(ISA),但具有膜稳定作用(MSE),索他洛尔(β1 + β2肾上腺素受体阻滞,无ISA,无MSE)和阿替洛尔(β1肾上腺素受体阻滞,无ISA,无MSE),所有参数均显着增加。当具有ISA但无MSE的匹多洛尔(β1+β2-肾上腺素受体阻滞剂)和匹索洛尔(β1-肾上腺素受体阻滞剂)达到β-肾上腺素受体阻滞剂时,所有参数均保持不变,(+)-普萘洛尔,具有MSE但不具有ISA和β-肾上腺皮质激素特性。 3高剂量的异丙肾上腺素可显着缩短不应期,但停止输注时,可观察到明显但可逆的传导抑制。 4因此,似乎是β-肾上腺素受体阻滞而不是MSE引起了心房和房室传导障碍的发作,并且ISA为这种损伤提供了保护。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号